Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised active-controlled study of AMG 162 in breast cancer with bone metastases
2004-000509-24Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of denosumab in breast cancer (3 arms), sponsored by Amgen. Primary endpoint: Percentage change from baseline to week 13 in urinary N-telopeptide (uNTx). Started Jul 2004; status: completed.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-000509-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000509-24.